Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
News provided byJnana Therapeutics, Inc.
Nov 21, 2023, 8:00 AM ET
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 9:50 a.m. ET.
About Jnana Therapeutics
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation RAPID chemoproteomics platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet needs. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases and immune-mediated diseases. Jnana’s wholly owned lead program, JNT-517, which targets an allosteric site on the phenylalanine transporter SLC6A19, is a potential first-in-class oral approach for the treatment of PKU, a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team, and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures, and AbbVie Ventures. For more information, please visit www.jnanatx.com and follow us on Twitter/X and LinkedIn.
Investor Contact Josh Rappaport Stern Investor Relations, Inc. firstname.lastname@example.org Media Contact Adam Silverstein Scient PR email@example.com
NOTE: This content is not written by or endorsed by "KWKT/KYLE", its advertisers, or Nexstar Media Inc.